| HOME >> BIOLOGY >> TECHNOLOGY |
LYNBROOK, N.Y., Sept. 24 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (OTC Bulletin Board: BSTC), a biopharmaceutical company developing first in class collagenase based products, today announced the appointment of Matthew Geller, Ph.D., to its Board of Directors, increasing the Board to 7 members. Dr. Geller brings to BioSpecifics extensive financial experience with biotechnology companies as he has served for over 15 years as a sell-side analyst and investment banker covering biotechnology companies.
"We are very pleased that Dr. Geller is joining our Board. His financial and scientific acumen and extensive experience in the industry will be invaluable to our organization as our lead collagenase product XIAFLEX(TM) moves through late-stage clinical trials and towards the marketplace," stated Thomas Wegman, President of BioSpecifics Technologies Corp. "We look forward to his many strategic contributions."
"I consider it a great honor to be invited to join BioSpecifics' Board," said Dr. Geller. "Having demonstrated its ability to successfully develop an approved product and to develop through a pivotal phase III trial a potential blockbuster drug that fills a large unsatisfied patient need, BioSpecifics now has the opportunity to emerge as a major financial success. It is a privilege to participate in and contribute to this great step forward."
Dr. Geller will serve as the financial expert on the audit committee and will be an independent class 1 director.
Dr. Geller has been a Principal with Torreya Partners, a life sciences
advisory firm. He formerly served as Head of Healthcare Investment Banking
and Senior Managing Director for Rodman & Renshaw, ranked number one in
PIPE transactions and registered direct transactions. Prior to Rodman &
Renshaw, he served as Senior Biotechnology Analyst at Oppenheimer and CIBC
World Markets for 12 years. He was consistently ranked as the top analyst
at the firm both internally and
'/>"/>
| SOURCE BioSpecifics Technologies Corp. Copyright©2008 PR Newswire. All rights reserved |